Wellington Management Group LLP Reduces Stock Position in Insulet Corporation $PODD

Key Points

• Wellington Management cut its Insulet stake by 84.5% in the second quarter, selling 91,010 shares and retaining 16,744 shares valued at approximately $2.55 million.
• Insulet’s shares opened at $134.68, down 2.3%, and remain well below their 12-month high of $354.88. The stock has a consensus “Hold” rating with an average analyst price target of $195.40.
• The company reported better-than-expected quarterly results, with EPS of $1.66 versus estimates of $1.47 and revenue of $801.7 million, up 23.5% year over year.

Wellington Management Group LLP reduced its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 84.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,744 shares of the medical instruments supplier's stock after selling 91,010 shares during the period. Wellington Management Group LLP's holdings in Insulet were worth $2,549,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the stock. Glenmede Investment Management LP lifted its holdings in Insulet by 1.6% during the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier's stock worth $708,000 after purchasing an additional 35 shares in the last quarter. Curi Capital LLC boosted its stake in Insulet by 0.8% in the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier's stock worth $1,365,000 after purchasing an additional 36 shares during the period. Great Lakes Advisors LLC grew its holdings in Insulet by 1.5% during the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier's stock valued at $791,000 after buying an additional 40 shares in the last quarter. Camarda Financial Advisors LLC grew its holdings in Insulet by 0.5% during the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier's stock valued at $2,304,000 after buying an additional 40 shares in the last quarter. Finally, Larson Financial Group LLC increased its position in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock valued at $25,000 after buying an additional 47 shares during the period.

Insulet Trading Down 2.3%

NASDAQ PODD opened at $134.68 on Friday. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The stock's 50-day simple moving average is $153.01 and its two-hundred day simple moving average is $174.22. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88. The company has a market capitalization of $9.34 billion, a price-to-earnings ratio of 25.17, a PEG ratio of 1.09 and a beta of 1.08.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.47 by $0.19. The firm had revenue of $801.70 million during the quarter, compared to analysts' expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company's revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. Research analysts forecast that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Analysts Set New Price Targets

PODD has been the topic of a number of recent analyst reports. Canaccord Genuity Group lowered their price target on shares of Insulet from $249.00 to $179.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Wells Fargo & Company lowered shares of Insulet from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $255.00 to $144.00 in a report on Wednesday, August 5th. Robert W. Baird set a $175.00 target price on shares of Insulet in a research note on Thursday, August 6th. BTIG Research downgraded shares of Insulet from a "buy" rating to a "neutral" rating in a report on Thursday, August 6th. Finally, Citigroup raised their price target on shares of Insulet from $165.00 to $172.00 and gave the company a "neutral" rating in a report on Wednesday, July 8th. Fourteen analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $195.40.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.